Abstract
Cholecystokinin modulates pain and anxiety via its functions within brain regions such as the midbrain periaqueductal gray (PAG). The aim of this study was to examine the cellular actions of cholecystokinin on PAG neurons. Whole-cell patch clamp recordings were made from rat midbrain PAG slices in vitro to examine the postsynaptic effects of cholecystokinin and its effects on synaptic transmission. Sulfated cholecystokinin-(26–33) (CCK-S, 100–300 nM), but not non-sulfated cholecystokinin-(26–33) (CCK-NS, 100–300 nM) produced an inward current in a sub-population of opioid sensitive and insensitive PAG neurons, which did not reverse over a range of membrane potentials. The CCK-S-induced current was abolished by the CCK1 selective antagonist devazepide (100 nM), but not by the CCK2 selective antagonists CI988 (100 nM, 1 μM) and LY225910 (1 μM). CCK-S, but not CCK-NS produced a reduction in the amplitude of evoked GABAA-mediated inhibitory postsynaptic currents (IPSCs) and an increase in the evoked IPSC paired-pulse ratio. By contrast, CCK-S had little effect on the rate and amplitude of TTX-resistant miniature IPSCs under basal conditions and when external K+ was elevated. The CCK-S-induced inhibition of evoked IPSCs was abolished by the cannabinoid CB1 receptor antagonist AM251 (3 μM), the mGluR5 antagonist MPEP (10 μM) and the 1, 2-diacylglycerol lipase (DAGLα) inhibitor tetrahydrolipstatin (10 μM). In addition, CCK-S produced an increase in the rate of spontaneous non-NMDA-mediated, TTX-dependent excitatory postsynaptic currents (EPSCs). These results suggest that cholecystokinin produces direct neuronal depolarisation via CCK1 receptors and inhibits GABAergic synaptic transmission via action potential-dependent release of glutamate and mGluR5-induced endocannabinoid signaling. Thus, cholecystokinin has cellular actions within the PAG that can both oppose and reinforce opioid and cannabinoid modulation of pain and anxiety within this brain structure.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bertoglio LJ, Zangrossi Jr H (2005). Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats. Brain Res 1059: 46–51.
Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A et al (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463–468.
Brack KE, Jeffery SM, Lovick TA (2006). Cardiovascular and respiratory responses to a panicogenic agent in anaesthetised female Wistar rats at different stages of the oestrous cycle. Eur J Neurosci 23: 3309–3318.
Brack KE, Lovick TA (2007). Neuronal excitability in the periaqueductal grey matter during the estrous cycle in female Wistar rats. Neuroscience 144: 325–335.
Carlberg M, Gundlach AL, Mercer LD, Beart PM (1992). Autoradiographic localization of cholecystokinin A and B receptors in rat brain using [125I]d-Tyr25 (Nle28,31)-CCK 25–33S. Eur J Neurosci 4: 563–573.
Chen XH, Geller EB, Adler MW (1998). CCK(B) receptors in the periaqueductal grey are involved in electroacupuncture antinociception in the rat cold water tail-flick test. Neuropharmacology 37: 751–757.
Chhatwal JP, Gutman AR, Maguschak KA, Bowser ME, Yang Y, Davis M et al (2009). Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 34: 509–521.
Connor M, Bagley EE, Mitchell VA, Ingram SL, Christie MJ, Humphrey PPA et al (2004). Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro. Br J Pharmacol 142: 1273–1280.
Drew GM, Lau BK, Vaughan CW (2009). Substance P Drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J Neurosci 29: 7220–7229.
Drew GM, Mitchell VA, Vaughan CW (2005). Postsynaptic actions of substance P on rat periaqueductal grey neurons in vitro. Neuropharmacology 49: 587–595.
Drew GM, Mitchell VA, Vaughan CW (2008). Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling. J Neurosci 28: 808–815.
Faris PL, Komisaruk BR, Watkins LR, Mayer DJ (1983). Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219: 310–312.
Fields HL, Basbaum AI, Heinricher MM (2006). Central nervous systems mechanisms of pain modulation. In: McMahon SB, Koltzenburg M (eds). Textbook of Pain, 5th edn. Elsevier, Churchill Livingston: Philadelphia, pp 125–142.
Finn DP, Jhaveri MD, Beckett SRG, Roe CH, Kendall DA, Marsden CA et al (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45: 594–604.
Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM (1993). Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58: 123–131.
Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R et al (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108–1112.
Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M et al (2005). Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68: 1196–1202.
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309–380.
Keay KA, Bandler R (2001). Parallel circuits mediating distinct emotional coping reactions to different types of stress. Neurosci Biobehav Rev 25: 669–678.
Kubota Y, Inagaki S, Shiosaka S, Cho HJ, Tateishi K, Hashimura E et al (1983). The distribution of cholecystokinin octapeptide-like structures in the lower brain stem of the rat: an immunohistochemical analysis. Neuroscience 9: 587–604.
Kurrikoff K, Inno J, Matsui T, Vasar E (2008). Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin. Eur J Neurosci 27: 2147–2155.
Lau BK, Vaughan CW (2008). Muscarinic modulation of synaptic transmission via endocannabinoid signalling in the rat midbrain periaqueductal gray. Mol Pharmacol 74: 1392–1398.
Li Y, Han JS (1989). Cholecystokinin-octapeptide antagonizes morphine analgesia in periaqueductal gray of the rat. Brain Res 480: 105–110.
Lichtman AH, Cook SA, Martin BR (1996). Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276: 585–593.
Liu H, Chandler S, Beitz AJ, Shipley MT, Behbehani MM (1994). Characterization of the effect of cholecystokinin (CCK) on neurons in the periaqueductal gray of the rat: immunocytochemical and in vivo and in vitro electrophysiological studies. Brain Res 642: 83–94.
Lovick TA (2008). Pro-nociceptive action of cholecystokinin in the periaqueductal grey: a role in neuropathic and anxiety-induced hyperalgesic states. Neurosci Biobehav Rev 32: 852–862.
Luo B, Cheu JW, Siegel A (1998). Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat. Brain Res 796: 27–37.
Mercer LD, Beart PM (2004). Immunolocalization of CCK1R in rat brain using a new anti-peptide antibody. Neurosci Lett 359: 109–113.
Mercer LD, Beart PM, Horne MK, Finkelstein DI, Carrive P, Paxinos G (1996). On the distribution of cholecystokinin B receptors in monkey brain. Brain Res 738: 313–318.
Mitchell VA, Kawahara H, Vaughan CW (2009). Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey. J Physiol (Lond) 587: 2511–2520.
Moreira FA, Aguiar DC, Guimaraes FS (2007). Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52: 958–965.
Netto CF, Guimaraes FS (2004). Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray. Neuropsychopharmacology 29: 101–107.
Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M et al (1999). International Union of Pharmacology. XXI. structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 51: 745–781.
Osborne PB, Vaughan CW, Wilson HI, Christie MJ (1996). Opioid inhibition of rat periaqueductal grey neurones with identified projections to rostral ventromedial medulla in vitro. J Physiol (Lond) 490: 383–389.
Reichling DB, Basbaum AI (1990). Contribution of brain-stem GABAergic circuitry to descending antinociceptive controls.1. GABA-immunoreactive projection neurons in the periaqueductal gray and nucleus raphe magnus. J Comp Neurol 302: 370–377.
Resstel LB, Lisboa SF, Aguiar DC, Correa FM, Guimaraes FS (2008). Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology 198: 405–411.
Smeets RL, Fouraux MA, van Emst-de Vries SE, De Pont JJ, Willems PH (1998). Protein kinase C-mediated inhibition of transmembrane signalling through CCK(A) and CCK(B) receptors. Brit J Pharmacol 123: 1189–1197.
Tortorici V, Nogueira L, Salas R, Vanegas H (2003). Involvement of local cholecystokinin in the tolerance induced by morphine microinjections into the periaqueductal gray of rats. Pain 102: 9–16.
Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007). Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27: 3663–3676.
Vaughan CW, Christie MJ (1997). Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol (Lond) 498: 463–472.
Vaughan CW, Connor M, Bagley EE, Christie MJ (2000). Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57: 288–295.
Yang YM, Chung JM, Rhim H (2006). Cellular action of cholecystokinin-8S-mediated excitatory effects in the rat periaqueductal gray. Life Sci 79: 1702–1711.
Yang YM, Chung JM, Rhim H (2007). Cholecystokinin-8S-induced intracellular calcium signaling in acutely isolated periaqueductal gray neurons of the rat. Biol Pharm Bull 30: 297–302.
Acknowledgements
This work was supported by Australian National Health and Medical Research Council grant 1003097 to CWV and GMD.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Mitchell, V., Jeong, HJ., Drew, G. et al. Cholecystokinin Exerts an Effect via the Endocannabinoid System to Inhibit GABAergic Transmission in Midbrain Periaqueductal Gray. Neuropsychopharmacol 36, 1801–1810 (2011). https://doi.org/10.1038/npp.2011.59
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2011.59
Keywords
This article is cited by
-
Whey protein supplementation reducing fasting levels of anandamide and 2-AG without weight loss in pre-menopausal women with obesity on a weight-loss diet
Trials (2020)
-
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
Neurological Sciences (2020)
-
Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence
BMC Neuroscience (2012)
